Fiche publication
Date publication
mars 2021
Journal
Cells
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MULLER Sylviane
Tous les auteurs :
Talamini L, Matsuura E, De Cola L, Muller S
Lien Pubmed
Résumé
The current therapies based on immunosuppressant or new biologic drugs often show some limitations in term of efficacy and applicability, mainly because of their inadequate targeting and of unwanted adverse reactions they generate. To overcome these inherent problems, in the last decades, innovative nanocarriers have been developed to encapsulate active molecules and offer novel promising strategies to efficiently modulate the immune system. This review provides an overview of how it is possible, exploiting the favorable features of nanocarriers, especially with regard to their immunogenicity, to improve the bioavailability of novel drugs that selectively target immune cells in the context of autoimmune disorders and inflammatory diseases. A focus is made on nanoparticles that selectively target neutrophils in inflammatory pathologies.
Mots clés
NETosis, drug targeting, immunomodulation, nanoparticles, neutrophils, therapeutic carriers
Référence
Cells. 2021 Mar 23;10(3):
